Prothena Corporation plc
PRTA Healthcare Biotechnology
Prothena Corporation plc’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS grew 84.6% and free cash flow grew 44.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PRTA
Prothena Corporation plc (PRTA) EV/Sales
As of 12 October 2026, Prothena Corporation plc (PRTA) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from −156× (August 2019) to 2,266× (June 2021); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 21.3× | 954.51% |
| FY2024 | 2.0× | (87.08%) |
| FY2023 | 15.7× | (53.72%) |
| FY2022 | 33.8× | 322.63% |
| FY2021 | 8.0× | (96.26%) |
| FY2020 | 214× | (31.81%) |
| FY2019 | 314× | — |
| FY2018 | −21.2× | — |
| FY2017 | 36.5× | (97.09%) |
| FY2016 | 1,254× | 18.94% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.1× | 22.65% |
| Mar 2026 | 3.3× | (84.42%) |
| Dec 2025 | 21.3× | 29.21% |
| Sep 2025 | 16.5× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | 1.5× |
| PRTA Prothena Corporation plc | 2.8× |
| EDIT Editas Medicine, Inc. compare | 3.2× |
| CAPR Capricor Therapeutics, Inc. compare | 9.4× |
| ENTX Entera Bio Ltd. compare | 534× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)